5th Conference on Retroviruses and Opportunistic Infections


Chicago, IL - February 1-5, 1998



ANTIRETROVIRAL EFFECTS OF THERAPY COMBINING ABACAVIR (1592) WITH HIV PROTEASE INHIBITORS (PIS)

Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:79 (abstract no. 4)

Mellors J, Lederman M, Haas D, Horton J, Haubrich R, Stanford J, Cooney E, McMahon D, Spreen W, Smiley M, Kelleher D
University of Pittsburgh Medical Center, Pittsburgh, PA.

OBJECTIVE: Assess safety and antiretroviral activity of abacavir combined with 5 different potent PIs.

METHODS AND MATERIALS: Eighty antiretroviral naïve HIV-infected adult subjects with CD4+ cells greater than 100 and HIV-RNA greater than 5,000 cps/mL were enrolled into this open-label trial. Subjects were randomized to receive abacavir (300mg, ql2h) in combination with one of five different PIs: 141 (1200mg,ql2h), indinavir (800mg, q8h), ritonavir (600mg, ql2h), saquinavir.sgc (1200mg, q8h), nelfinavir (750mg, q8h). Viral load was quantified by HIV-RNA PCR (Roche Amplicor).

RESULTS: Preliminary results from 64/80 patients indicate that abacavir was well tolerated in combination with 5 different PIs. Four subjects prematurely discontinued due to possible study drug reaction. Median viral load decreases from base-line through day 28 are shown below. Data through 16 weeks will be presented.

Treatment
1592                     (N)		 Baseline
(log10 cps/mL)		 Day 7 Day 14 Day 21 Day 28 Wk 8 Wk 16
141                     (13) 5.09 -1.30 -1.69 -1.90 -1.96 * *
Indinavir              (13) 4.61 -1.14 -1.73 -1.65 -1.93 * *
Ritonavir             (12) 4.48 -1.11 -1.46 -1.84 -1.78 * *
Saquinavir          (14) 4.82 -1.23 -1.62 -1.63 -1.85 * *
Nelfinavir            (12) 4.84 -1.34 -1.66 -1.86 -2.05 * *

CONCLUSIONS: Abacavir (300 mg, ql2h) in dual combination with 5 different PIs was well tolerated and demonstrated potent antiretroviral activity.

Keywords: AEGIS, HIV Protease Inhibitors, Dideoxynucleosides, Ritonavir, Saquinavir, Indinavir, Anti-HIV Agents, Viral Load, Nelfinavir, Reverse Transcriptase Inhibitors, HIV Infections, HIV, HIV-1 Reverse Transcriptase, abacavir, Adult, Human, therapy, drug therapy, AIDS

Acrobat ReaderDownload abstract

1998-02-01
4

Copyright © 1998 - Foundation for Retrovirology and Human Health (IAS). Reproduction of this abstract (other than one copy for personal reference) must be cleared through the Foundation for Retrovirology and Human Health. Licensed from National Library of Medicine.